The company is looking to raise about US$150 million to US$200 million as soon as this year
Published Fri, Aug 22, 2025 · 07:02 PM
[HONG KONG] Chinese surgical robot firm Edge Medical, backed by Singapore state investor Temasek Holdings, has filed confidentially for a Hong Kong initial public offering, according to people familiar with the matter.
The Shenzhen-headquartered company is looking to raise about US$150 million to US$200 million as soon as this year, the people said, asking not to be identified because the information isn’t public.
GF Securities and Morgan Stanley are working on the IPO, the people said. Details of the offering such as size and timing are preliminary and may change, they said.
Representatives for GF and Morgan Stanley declined to comment. Edge Medical didn’t respond to requests for comment.
Edge Medical previously filed for a Hong Kong IPO in 2022, but the market ended up sliding to its lowest since 2009 that October. Now it’s looking to list as Chinese health-care and biotech firms find favour among investors again. The Hang Seng Biotech Index has almost doubled since the start of the year on enthusiasm about foreign firms licensing Chinese drugs.
Guangzhou Innogen Pharmaceutical Group tripled on its Hong Kong trading debut this month after retail investors bid for more than 5,000 times the number of shares available to them. Ab&B Bio-Tech has soared nearly 300 per cent since it started trading in Hong Kong about two weeks ago, while other strong stocks include Nanjing Leads Biolabs, which has doubled since July.
Founded in 2017, Edge Medical offers multi-port, single-port and bronchoscopic surgical robots. It was valued at over US$1.5 billion in a crossover round in 2021, its website shows. Its other investors include Boyu and OrbiMed Advisors. BLOOMBERG
Share with us your feedback on BT’s products and services
